Current Issues of Pharmacy and Medical Sciences

Doxorubicin induces delayed heart and liver mitochondrial depolarisation

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 1, Pages 21-25

SLAWOMIR MANDZIUK1*, LENA BIS2, KATARZYNA BURY2, AGNIESZKA KORGA2,FRANCISZEK BURDAN3, JAROSLAW DUDKA2

1 Oncological Pneumology and Alergology Department, Medical University of Lublin, Poland

2 Medical Biology Unit, Medical University of Lublin, Poland

3 Human Anatomy Department, Medical University of Lublin, Poland


DOI: 10.12923/j.2084-980X/26.1/a.04

Abstract

The effect of repeated administration of doxorubicin (DOX) on heart and liver morphology, mitochondrial function and redox equilibrium was investigated in rats, contributing in explanation of delayed cardiomyopathy. Male Wistar rats were weekly intraperitoneally exposed to doxorubicin (1.5 mg/kg to achieve cumulative dose of 18 mg/kg). To assess persistence changes the heart and liver were studied 3 weeks after last drug administration. Histological examination did not reveal any significant changes in heart and liver in drug-treated animals. However, mitochondrial depolarisation was observed in both organs. These changes in the liver were accompanied by significant increasing in mitochondrial oxidised glutathione and marked decrease of reduced/oxidised glutathione ratio. No changes in cardiac and hepatic NADPH and NADH levels were found. The depolarisation of mitochondria of both studied organs after three weeks since the last injection seems to be a programmed effect of the drug. It may be assumed that this is an early physiological change leading to mitochondrial insufficiency and consequently the cardiac failure.

Keywords

doxorubicin, delayed cardiotoxicity, redox equilibrium, mitochondrial depolarisation

References

  1. Berthiaume J.M. and Wallace K.B.: Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol., 23 15, 2007.
  2. Berthiaume J.M. and Wallace K.B.: Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment. Cardiovasc. Toxicol., 7, 178, 2007.
  3. Dudka J. et al.: Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study. Basic. Clin. Pharmacol. Toxicol., 97, 74, 2005.
  4. Dudka J.: The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity. Postepy Hig. Med. Dosw.,  60, 241, 2006.
  5. Green P.S. and Leeuwenburgh C.: Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim. Biophys. Acta, 1588, 94, 2002.
  6. Halestrap A.P.: Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem. Soc. Trans.,  34, 232, 2006.
  7. Hoek J.B. and  Rydström J. Physiological roles of nicotinamide nucleotide transhydrogenase. Biochem. J.  254, 1, 1988.
  8. Kawasaki N. et al.: Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats. Int. J. Cardiol., 55, 217, 1996.
  9. Lebrecht D. and Walker U.A.: Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc. Toxicol., 7, 108, 2007.
  10. Meredith M.J. and Reed D.J.: Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem. Pharmacol.,  32: 1383, 1983.
  11. Minotti G.: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 56, 185, 2004.
  12. Montaigne D. et al.: Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicol. Appl. Pharmacol., 244, 300, 2010.
  13. Mross K. et al.: Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J. Clin. Oncol.,  6, 517, 1988.
  14. Pointon AV, et al.: Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One 5:e127332010.
  15. Sokolove P.M.: Inhibition by cyclosporin A and butylated hydroxytoluene of the inner mitochondrial membrane permeability transition induced by adriamycin aglycones. Biochem. Pharmacol. 40, 2733, 1990.
  16. Solem L.E., Heller L.J. and Wallace K.B.: Dose-dependent increase in sensitivity to calcium-induced mitoand chondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J. Mol. Cell Cardiol.,  28, 1023, 1996.
  17. Spallarossa P. et al.: Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell Cardiol., 37, 837, 2004.
  18. Taskin E., Dursun N.: The protection of selenium on adriamycin-induced mitochondrial damage in rat. Biol. Trace. Elem. Res., 147, 165, 2012.
  19. Valls-Belles V., Torres C., Muñiz P. and Codoñer-Franch P.: Effect of beer consumption on levels of complex I and complex IV liver and heart mitochondrial enzymes and coenzymes Q9 and Q10 in adriamycin-treated rats. Eur. J. Nutr. 49, 181, 2010.
  20. Wencker D. et al.: A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest., 111, 1497, 2003.
prev next

 

Calendar

April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30